Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Let's assume Brilacidin is the next Penicillin or Humira, as some have claimed here. Let's also assume you are the CEO of a BP. You have two options.
1. Do what Pete said and try to suppress IPIX's stock for many years until it either bankrupts or B's patent expires. You hope Leo will become desperate and sell B to you well below market value.
2. You offer fair market value for B-ABSSSI in 2014 and B-OM in 2018. By now you are making billions of revenue every year. Doctors could even prescribe B-COVID off-label since B is already approved.
Which option do you think will make you look good and your shareholders happy?
1. Telling your shareholders you are still suppressing a penny stock so you can acquire B for cheap one day.
2. You are the person who acquired the next Penicillin or Humira and your stock is at all-time high.
Hi LilKahuna, hope things are well. I remember the total OS was around 91M when I first invested 10 years ago, that's why I said it was under 100M.
You hit the nail on the head. They have to find something (without proof) to explain the SP since they'll never say anything bad about Leo/IPIX. Their mindset is still at 10 years ago when the total OS was under 100M and the daily volume was under 100K shares. So when the daily volume is 500K shares or more, they claim most of them are fake/naked because longs they know are not selling therefore no one is selling. They assume the 350M shares dilution were all absorbed by longs. Even at 1M shares the daily volume is ~0.2% of the total OS. I guess they think 0.2% is too much selling so they can't be real shares.
I didn't say Dr. DeGrado's resume isn't impressive. My point was that it doesn't always translate to the commercialization of Brilacidin. Many here have said the same about Dr. Menon. Some even said he's going to win the Nobel Prize in Medicine. He still might, but We all know where is Kevetrin at the moment.
Let's look at this resume - Chairman of NASDAQ, 1990. That sounds very impressive to me. Would you feel safe investing your money in his company back in 1990? Do you really know this person besides what's written on his resume? I'm not implying Dr. DeGrado is Bernie Madoff but I hope you see my point.
Pete, I agree it's a good sign, but not sure how the FDA knows the result is good since unblinding is not expected until mid-October. FWIW Remdesivir was granted compassionate use in adults, pregnant women and children before.
Compassionate Use of Remdesivir for Patients with Severe Covid-19
https://pubmed.ncbi.nlm.nih.gov/32275812/
Compassionate Use of Remdesivir in Pregnant Women With Severe Coronavirus Disease 2019
https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1466/5919737
Compassionate Use of Remdesivir in Children With Severe COVID-19
https://pediatrics.aappublications.org/content/147/5/e2020047803
I'm not trying to discredit Dr. DeGrado. Dr. Bertolino was a senior Director of Dermatology at Pfizer, which I thought was pretty impressive. Some said Dr. Menon's background was impressive also. But Prurisol failed, Kevetrin is on the shelf, and neither person is with the company anymore. We really don't know anything about the person besides what's written on their resume.
I used to think the same about Prurisol. Leo announced database lock on 6/29/2018.
https://www.ipharminc.com/press-release/2018/6/29/innovation-pharmaceuticals-announces-database-lock-for-phase-2b-trial-of-oral-prurisol-for-psoriasis
Then this in the 10-K three months later.
A Phase 3 was scheduled for 2015.
https://www.ipharminc.com/press-release/2016/11/16/cellceutix-provides-brilacidin-update-new-class-of-antibiotics-to-enter-phase-3
Then again for 2018.
https://www.ipharminc.com/press-release/2018/12/17/innovation-pharmaceuticals-completes-end-of-phase-2-meeting-with-fda-brilacidin-oral-rinse-to-advance-into-phase-3-clinical-trials-for-prevention-of-severe-oral-mucositis
Last year's 10-K was filed on 9/14/20. Does anyone know when is the latest Leo has to file this year?
I read elsewhere that Leo should not PR today and tomorrow because may people will miss it due to Rosh Hashanah. This might be true if the majority of US population are Jewish.
Very sad to see this! =( We sure had some good times together. I hope IPIX can make you proud in heaven one day. RIP Gov!
Pete, sometimes you said BPs are afraid of Brilacidin taking away their profit so they are in cahoots with the government to slow IPIX down. Sometimes (like today) you said plenty of BPs want to partner with IPIX for the whole B platform. I'm not here to debate which one is more likely, but I hope you see one contradicts the other. I always believe that if you have the goods, BPs (regardless of location) will pay so they can replenish their pipeline and increase their revenue. The "conspiracy theories" are simply excuses to take the blame away from Leo when things did not go according to plan IMO.
IPIX has $12.1M cash on hand so it should be enough to finish the remaining half of toxicology studies for K if Leo wants to.
Article - US has bought and will donate 500 million doses of Pfizer's vaccine worldwide
https://www.cnn.com/2021/06/09/politics/us-buys-pfizer-doses-to-donate/index.html
I'm not saying therapeutics are not needed, but the world is not standing still when it comes to vaccination. All the speculations about Brilacidin curing COVID-19 and all variants and all pan-coronaviruses are hypothetical at this point.
Nice find. Since the SEC charged the trading firm, I assume they found some kind of credible evidence. For years AlanC claims naked shorting in IPIX is a perfect crime without any trace of evidence. While I agree that naked shorting exists in IPIX, I disagree on the amount Alan is claiming (400 million fake shares and counting).
The first speaker mentioned fails-to-deliver as an indication of naked shorting. Here's IPIX's fails-to-deliver data for the past four years. The most recent number was 68,837 shares on 4/22/21.
https://sec.report/fails.php?tc=IPIX
This article lost me when it claimed the amount involved could be more than the global GDP in 2020 ($84.5 trillion), but anyone can sue for anything in the US.
Since James Christian planned to file the lawsuit, I assume he found some kind of evidence of naked shorting. Maybe Leo should hire him to do the same for IPIX. The potential reward is a billion dollar so why not give it a try?
GME and AMC had very high legal short positions, but IPIX does not. As for naked shorting,
Alan, do the naked shorts need to pay interest for the 300 million shares (your estimate if I remember correctly)? If so, how much do you think is the cost to borrow?
LifeSiteNews is owned by Campaign Life Coalition, a Christian conservative organization.
https://en.wikipedia.org/wiki/Campaign_Life_Coalition
Pete, we don't know how long it took IPIX/CRO to submit the required safety data to the FDA for review. Data had to be unblinded first for find out who received B. But I agree that the FDA is notoriously slow.
I wanted to reply to your other post which I couldn't find it anymore. Saying Leo is dishonest is similar to saying he's honest. Both are opinions which we can't prove. Only Leo knows the truth. The difference is you don't like to hear one of them. There are plenty of examples where Leo said something but failed to do it. I listed some of them last week.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=163911022
Prurisol interim data and Nasdaq uplisting also come to mind. These were important milestones that could have significant impact on the stock.
Pro: Leo planned to start B-ABSSSI Phase 3 trials seven years ago.
http://www.ipharminc.com/press-release/2016/11/16/cellceutix-to-start-brilacidin-phase-3-program-in-absssi
Con: Phase 3 trial = 0
Pro: Leo planned to start B-OM Phase 3 trials three years ago.
http://www.ipharminc.com/press-release/2018/12/17/innovation-pharmaceuticals-completes-end-of-phase-2-meeting-with-fda-brilacidin-oral-rinse-to-advance-into-phase-3-clinical-trials-for-prevention-of-severe-oral-mucositis
Con: Phase 3 trial = 0
Pro: Leo was "laser-focused" on partnerships five years ago.
http://www.ipharminc.com/press-release/2016/12/22/cellceutix-wishes-shareholders-happy-holidays-prepares-for-2017-focused-on-partnerships
Con: Partnership (a real one with non-dilutive funding) = 0
Pro: Leo failed to find a partner so he hired Locust Walk not once but twice.
http://www.ipharminc.com/press-release/2019/9/30/innovation-pharmaceuticals-engages-locust-walk-a-global-life-sciences-transaction-firm
http://www.ipharminc.com/press-release/2020/1/29/innovation-pharmaceuticals-further-engages-locust-walk-to-lead-out-licensing-negotiations-for-rights-to-phase-3-ready-oral-mucositis-drug-candidate
Con: Partnership for B-OM = 0
Here's the truth.
How convenient Tucker did not mention the second part.
I agree that vaccines are not 100% effective in preventing infections, but they are 100% effective in preventing hospitalizations and deaths. That's most important IMO.
Vaccines Are 100% Effective at Preventing COVID-19 Hospitalizations and Deaths
https://reason.com/2021/02/23/vaccines-are-100-effective-at-preventing-covid-19-hospitalizations-and-deaths/
All the Covid-19 vaccines prevent death and severe disease, and that's what matters, experts say
https://www.cnn.com/2021/03/22/health/covid-vaccines-prevent-death/index.html
Pfizer CEO: No variant identified so far can escape our vaccine protection
Comparing IPIX to Dogecoin is an insult to all joking memecoins LOL. At least one thing they have in common is that both have unlimited supplies. My guess is that Leo will ask for another 300M authorized shares by year's end.
Well said! The market is asking what you got instead of what you speculate. Daily cases felt below 50,000 (-17%) and hospitalizations decreased another 10% since last week. Some said to look at what's happening in India and Brazil. But the FDA do not make decisions such as EUA based on other countries. We'll see what's the case count and hospitalization rate when IPIX is ready to report the result.
A better question would be why Aspire Capital sold hundreds of millions of shares since 2012 if they had faith in IPIX.
Although Section 564 did not specifically said Phase 3 is required, the FDA did require Phase 3 for COVID vaccines when the situation was much more dire last year in the US. Please see my other post for the source.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=163505380
Some argue that therapeutics are different than vaccines, but they both go into human bodies and could cause serious side effects. EUA is a good topic to discuss if data is positive. Let's not put the cart before the horse.
FWIW enrollment for B-ABSSSI Phase 2b trial was increased also. Leo said the reason was because some patients did not return for follow-up after 30 days. This could be one of the explanations, assuming the information is correct.
How do you explain Leo delayed the estimated primary completion date to July if enrollment is already at 84%?
I think you missed my point. I was not trying to compare Alexion to IPIX. My point was simple - it takes money to make money. If a BP invests $10B in IPIX, they believe the drugs acquired will make them more than $10B down the road. There are plenty of deals for drugs still under development. The sizes of the deals are usually smaller comparing to approved drugs.
Base on your logic, there would not be any major acquisitions by BPs because it would cost them money. In reality, here's the top 10 largest biotech M&A deals in 2020.
https://www.fiercepharma.com/special-report/top-10-largest-biopharma-m-a-deals-2020
Competitions among BPs are fierce. The same can be said for any industry. They need to replenish their portfolio and generate revenue constantly. Why did AstraZeneca spent $39B to acquire Alexion?
I see EUA being mentioned daily here. One of the requirements for COVID vaccines is Phase 3 data.
Having the majority of the trial take place in Russia is perplexing to me. Russia averages about 8,000 cases per day. As you know, majority of patients recover on their own. Among those moderate and severe patients, how many choose and qualify for the trial? Brilacidin is not the only choice in Russia.
In comparison, the US averages about 60,000 cases per day so there are a lot more potential patients. According to the CDC, there are about 6,000 new hospital admissions per day. So the US' hospitalization rate is almost the same as Russia's new case rate. It's Leo's decision on where to run the trial.
I see Pete's point. Telling the public that your pancoronavirus-killing wonder drug was enrolling at a pace of one patient per day across all sites in Russia and the US during a pandemic might not be so significant.
Pete, looks like your estimate was off since you expected enrollment is near 100%. You really can't blame American politics since the majority of enrollment takes place in Russia. Try to look within the company if you can't find a blame outside.
Farrell, hope things are well. Not sure what it meant, but the approval came at a time when the stock closed at 9 cents the previous trading day. It showed me what their priorities really were. Best of luck!
I'm not trying to minimize the diseases you mentioned, but I'm not going to get lung cancer, alcoholism, or obesity by standing in a crowd maskless. As tragic as those deaths are, they are not going to crush the healthcare system and kill the doctors/nurses treating the patients.
We are living through a once-in-a-lifetime pandemic. It's the contagiousness that separates COVID from lung cancer, alcoholism, and obesity. That's why we are hearing a lot more from the government and the media IMO.
Good luck with your IPIX investment!
That's the independent Board of Directors' job, whether they are highly qualified is debatable. Despite the constant declining stock price, they gave themselves a raise. At least we know they did something...
The answer can be found in the financial reports. Tens of millions of shares are being sold to Aspire each quarter. Aspire has yet to file Schedule 13G, meaning they have been selling in the open market. Do some math and you'll see how many shares Aspire is selling per day on average.
https://www.sec.gov/Archives/edgar/data/1355250/000147793221000999/ipix_10q.htm